Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hemoglobin Clear all

Conditions: Anaemia Postoperative
Interventions: Not listed
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: End Stage Kidney Disease (ESKD), Hyperglycaemia, Diabetes
Interventions: Continuous Glucose Monitoring (CGM); Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Postpartum Hemorrhage
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Postpartum Hemorrhage
Interventions: Oxytocin Infusion; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes Mellitus, Type 2, Obesity
Interventions: canagliflozin, Placebo (for canagliflozin); Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 20 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy, Surgery
Interventions: Rainbow DCI pulse oximeter sensor; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Irvine, California • Loma Linda, California • Jacksonville, Florida

Conditions: Anemia
Interventions: epoetin alfa or beta, methoxy polyethylene glycol-epoetin beta [Mircera]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 31
States / cities: Covina, California • Los Alamitos, California • Los Angeles, California + 23 more

Conditions: Renal Impairment
Interventions: GBT021601; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Lake Forest, California • Tustin, California • Miami, Florida + 1 more

Conditions: Sickle Cell Disease, Sickle Cell Anemia
Interventions: vorinostat; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Chronic Kidney Disease, End Stage Renal Disease, Anemia
Interventions: Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 4
States / cities: Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more

Conditions: Fracture of Posterior Wall of Acetabulum
Interventions: Tranexamic Acid, Normal saline; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Type 1 Diabetes Mellitus
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Tustin, California • Aurora, Colorado • New Haven, Connecticut + 12 more

Conditions: Type 1 Diabetes Mellitus
Interventions: CloudConnect Report, Will not receive a CloudConnect Report; Other
Lead sponsor: University of Virginia; Other
Eligibility: 12 Years to 17 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Peripheral Neuropathy, Chemotherapy-induced
Interventions: PROCRIT 40,000 IU QW, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 28
States / cities: Mobile, Alabama • Little Rock, Arkansas • Alhambra, California + 25 more

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 13 Years and older
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Healthy, Anemia
Interventions: Rad-67 Pulse oximeter & DCI Mini sensor; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
Interventions: Safety and efficacy assessments; Other
Lead sponsor: Editas Medicine, Inc.; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2040
U.S. locations: 16
States / cities: Oakland, California • Aurora, Colorado • New Haven, Connecticut + 12 more

Conditions: Cardiopulmonary Bypass, Cardiac Surgery, Kidney Injury, Acute
Interventions: Blood and urine collection; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sickle Cell Disease, Hemoglobinopathies
Interventions: EDIT-301; Genetic
Lead sponsor: Editas Medicine, Inc.; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 21
States / cities: Oakland, California • Aurora, Colorado • New Haven, Connecticut + 15 more

Conditions: Sickle Cell Disease
Interventions: Hydroxyurea; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 15 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Total Joint Arthroplasty
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules; Dietary Supplement · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 10 Years to 19 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Anesthesia
Interventions: Blood drawn; Diagnostic Test
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 40 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 50 mg, Placebo, Canagliflozin 150 mg, Metformin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 26
States / cities: Little Rock, Arkansas • National City, California • Spring Valley, California + 23 more

Search by objective public record fields.

Clinical Utility of Postoperative Hemoglobin Testing

Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring

Non-Invasive Measurement of Hemoglobin (Using Pulse Co-Oximetry) in Patients Undergoing Elective Cesarean Delivery

Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

Accuracy of Noninvasive Hemoglobin Measurement (SpHb) Using Rainbow DCI Pulse Oximeter Sensor

A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Study of GBT021601 in Participants With Renal Impairment

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin/Hematocrit

Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C

CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders

Noninvasive Hemoglobin Testing, Prospective Blood Donors

A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

Cardiopulmonary Bypass Induced Red Blood Cell Lysis

A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)

Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease

Non-invasive Hemoglobin Monitoring in Outpatient Total Joint Arthroplasty

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

The Effect of Hypotensive Anesthesia on Hemoglobin Levels During Total Knee Arthroplasty

An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy